In this article, we will look at the 8 Best Stem Cell Therapy Stocks to Buy.
On April 23, Bankim Chadha, chief global strategist at Deutsche Bank, appeared on CNBC’s ‘Money Movers’ to talk about uncertainty in the markets and what to expect with the earnings season.
He stated that he is not surprised at the market resilience in the face of risk factors such as the war, oil prices, and inflation, looking at the behavior of the S&P 500 and the equity market more broadly and historically around geopolitical events and risks. While there are some twists and turns this time, we have almost exactly followed the average or typical behavior of the market, which is a sharp selloff three weeks down 6-8%. He further stated that the surprising thing for most people is that the market tends to recover completely in another three weeks.
READ ALSO: 8 Best Low Priced Stocks to Buy Right Now AND 8 Best Bitcoin Stocks to Buy Now.
Chadha was of the view that if the equity market is doing what it always does, it is hard to say that it is getting optimistic or constructive. In his outlook, he expects the Fed to remain on hold near neutral through the remainder of 2026, and sees WTI crude averaging $90 a barrel in fiscal Q2, and falling gradually. He is not forecasting a recession, but a low-hiring, low-firing labor market remains a risk. Overall, Chadha believes that there is still a lot of upside in the markets.
With these broader market trends in view, let’s look at the best stem cell therapy stocks to buy now.
Our Methodology
We used stock screeners to compile a list of stocks involved with stem cell therapy and chose the top 8 with the highest number of hedge fund holders as of Q4 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.
Note: All data was recorded on April 23.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8 Best Stem Cell Therapy Stocks to Buy
8. Sanofi (NASDAQ:SNY)
Sanofi (NASDAQ:SNY) is one of the best stem cell therapy stocks to buy. Sanofi (NASDAQ:SNY) announced financial results for fiscal Q1 2026 on April 23, reporting double-digit sales and business EPS growth. Fiscal Q1 sales growth was 13.6% at CER, while business earnings per share reached €1.88. Pharma launches sales rose by 49.6% and reached €1.2 billion, driven primarily by Ayvakit, ALTUVIIIO, and Sarclisa.
Management further reported that Dupixent sales grew by 30.8% to €4.2 billion, suggesting a solid start to 2026. Similarly, vaccine sales grew by 2.1% to €1.3 billion, benefiting from Heplisav-B. Sanofi (NASDAQ:SNY) also announced that Research and Development expenses reached €1.7 billion, up by 1.5%, while selling and general expenses reached €2.3 billion, up by 11.6%, primarily due to the effect of recent acquisitions.
The company also provided insights into its pipeline progress, with five regulatory approvals, all in immunology, and positive pipeline readouts, including venglustat in the rare disease GD3 (phase 3) and lunsekimig in respiratory diseases (phase 2). Sanofi (NASDAQ:SNY) also reported two regulatory submission acceptances, one phase 3 study start, and four regulatory designations (breakthrough, orphan).
Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company’s operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.
7. AstraZeneca PLC (NYSE:AZN)
AstraZeneca PLC (NYSE:AZN) is one of the best stem cell therapy stocks to buy. AstraZeneca PLC (NYSE:AZN) announced on April 21 that positive high-level results from a prespecified interim analysis of the I CAN Phase III trial showed that Ultomiris met its primary endpoint, exhibiting a statistically significant and clinically meaningful reduction of proteinuria. This was based on a 24-hour urine protein creatinine ratio at week 34 in adults with immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. Management stated that the primary endpoint of change from baseline in estimated glomerular filtration rate (eGFR) will be measured at week 106.
AstraZeneca PLC (NYSE:AZN) also reported that the safety profile observed in the trial remained consistent with the known profile of Ultomiris, with no new safety concerns identified. According to the management, the company will seek accelerated approval in key markets and will present these results at a forthcoming medical meeting. IgAN is a rare, inflammatory disease of the kidneys that can result in chronic kidney disease (CKD) and progress to end-stage kidney disease (ESKD).
AstraZeneca PLC (NYSE:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians, and is involved in exploring novel immuno-oncology treatment approaches. AstraZeneca PLC (NYSE:AZN) distributes its products and services through local representative offices and distributors.
